KR20050010051A - 2,5-이중 치환된 3-머캅토펜탄산 - Google Patents
2,5-이중 치환된 3-머캅토펜탄산 Download PDFInfo
- Publication number
- KR20050010051A KR20050010051A KR10-2004-7020285A KR20047020285A KR20050010051A KR 20050010051 A KR20050010051 A KR 20050010051A KR 20047020285 A KR20047020285 A KR 20047020285A KR 20050010051 A KR20050010051 A KR 20050010051A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- compound
- optionally substituted
- formula
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201837-2 | 2002-06-14 | ||
| SE0201837A SE0201837D0 (sv) | 2002-06-14 | 2002-06-14 | Chemical compounds |
| PCT/SE2003/000970 WO2003106420A1 (en) | 2002-06-14 | 2003-06-10 | 2,5-disubstituted 3-mercaptopentanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050010051A true KR20050010051A (ko) | 2005-01-26 |
Family
ID=20288202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7020285A Ceased KR20050010051A (ko) | 2002-06-14 | 2003-06-10 | 2,5-이중 치환된 3-머캅토펜탄산 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7572817B2 (https=) |
| EP (1) | EP1532111B1 (https=) |
| JP (1) | JP2005533064A (https=) |
| KR (1) | KR20050010051A (https=) |
| CN (1) | CN100415719C (https=) |
| AR (1) | AR040240A1 (https=) |
| AT (1) | ATE369342T1 (https=) |
| AU (1) | AU2003241260B2 (https=) |
| BR (1) | BR0311384A (https=) |
| CA (1) | CA2488606A1 (https=) |
| CY (1) | CY1107753T1 (https=) |
| DE (1) | DE60315471T2 (https=) |
| DK (1) | DK1532111T3 (https=) |
| ES (1) | ES2289297T3 (https=) |
| IS (1) | IS7609A (https=) |
| MX (1) | MXPA04012604A (https=) |
| MY (1) | MY160429A (https=) |
| NO (1) | NO20045051L (https=) |
| NZ (1) | NZ536814A (https=) |
| PL (1) | PL373883A1 (https=) |
| PT (1) | PT1532111E (https=) |
| RU (1) | RU2365583C2 (https=) |
| SA (1) | SA03240142B1 (https=) |
| SE (1) | SE0201837D0 (https=) |
| TW (1) | TW200401766A (https=) |
| UA (1) | UA78042C2 (https=) |
| WO (1) | WO2003106420A1 (https=) |
| ZA (1) | ZA200409955B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| GB0403864D0 (en) * | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| NZ592764A (en) | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| AP2011005795A0 (en) | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. |
| HRP20190101T1 (hr) | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| FI4000608T3 (fi) | 2013-04-18 | 2026-01-21 | Boehringer Ingelheim Int | Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä |
| CA2914533A1 (en) | 2013-06-10 | 2014-12-18 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000066577A2 (en) * | 1999-04-29 | 2000-11-09 | Allergan Sales, Inc. | Brigded cycloalkanes as thromboxane ligands without blood clotting effects |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2002
- 2002-06-14 SE SE0201837A patent/SE0201837D0/xx unknown
-
2003
- 2003-06-02 AR ARP030101959A patent/AR040240A1/es unknown
- 2003-06-08 SA SA03240142A patent/SA03240142B1/ar unknown
- 2003-06-10 CN CNB038138409A patent/CN100415719C/zh not_active Expired - Fee Related
- 2003-06-10 ES ES03730987T patent/ES2289297T3/es not_active Expired - Lifetime
- 2003-06-10 KR KR10-2004-7020285A patent/KR20050010051A/ko not_active Ceased
- 2003-06-10 AT AT03730987T patent/ATE369342T1/de not_active IP Right Cessation
- 2003-06-10 PT PT03730987T patent/PT1532111E/pt unknown
- 2003-06-10 PL PL03373883A patent/PL373883A1/xx not_active Application Discontinuation
- 2003-06-10 EP EP03730987A patent/EP1532111B1/en not_active Expired - Lifetime
- 2003-06-10 AU AU2003241260A patent/AU2003241260B2/en not_active Ceased
- 2003-06-10 US US10/517,713 patent/US7572817B2/en not_active Expired - Fee Related
- 2003-06-10 DE DE60315471T patent/DE60315471T2/de not_active Expired - Fee Related
- 2003-06-10 RU RU2004134563/04A patent/RU2365583C2/ru not_active IP Right Cessation
- 2003-06-10 NZ NZ536814A patent/NZ536814A/en unknown
- 2003-06-10 MX MXPA04012604A patent/MXPA04012604A/es active IP Right Grant
- 2003-06-10 JP JP2004513253A patent/JP2005533064A/ja not_active Withdrawn
- 2003-06-10 DK DK03730987T patent/DK1532111T3/da active
- 2003-06-10 BR BR0311384-1A patent/BR0311384A/pt not_active IP Right Cessation
- 2003-06-10 CA CA002488606A patent/CA2488606A1/en not_active Abandoned
- 2003-06-10 WO PCT/SE2003/000970 patent/WO2003106420A1/en not_active Ceased
- 2003-06-12 TW TW092115988A patent/TW200401766A/zh unknown
- 2003-06-12 MY MYPI20032192A patent/MY160429A/en unknown
- 2003-10-06 UA UA20041109447A patent/UA78042C2/uk unknown
-
2004
- 2004-11-19 NO NO20045051A patent/NO20045051L/no not_active Application Discontinuation
- 2004-12-08 ZA ZA200409955A patent/ZA200409955B/en unknown
- 2004-12-22 IS IS7609A patent/IS7609A/is unknown
-
2007
- 2007-10-08 CY CY20071101274T patent/CY1107753T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60315471T2 (de) | 2008-04-24 |
| ZA200409955B (en) | 2006-08-30 |
| CN100415719C (zh) | 2008-09-03 |
| CN1662504A (zh) | 2005-08-31 |
| AU2003241260B2 (en) | 2007-04-26 |
| EP1532111B1 (en) | 2007-08-08 |
| CA2488606A1 (en) | 2003-12-24 |
| IS7609A (is) | 2004-12-22 |
| DE60315471D1 (de) | 2007-09-20 |
| WO2003106420A1 (en) | 2003-12-24 |
| BR0311384A (pt) | 2005-03-15 |
| SA03240142B1 (ar) | 2007-07-31 |
| NO20045051L (no) | 2005-01-13 |
| ES2289297T3 (es) | 2008-02-01 |
| MXPA04012604A (es) | 2005-03-23 |
| HK1077296A1 (en) | 2006-02-10 |
| UA78042C2 (en) | 2007-02-15 |
| PL373883A1 (en) | 2005-09-19 |
| NZ536814A (en) | 2006-11-30 |
| AR040240A1 (es) | 2005-03-23 |
| MY160429A (en) | 2017-03-15 |
| RU2365583C2 (ru) | 2009-08-27 |
| JP2005533064A (ja) | 2005-11-04 |
| ATE369342T1 (de) | 2007-08-15 |
| EP1532111A1 (en) | 2005-05-25 |
| AU2003241260A1 (en) | 2003-12-31 |
| PT1532111E (pt) | 2007-09-25 |
| CY1107753T1 (el) | 2013-04-18 |
| SE0201837D0 (sv) | 2002-06-14 |
| TW200401766A (en) | 2004-02-01 |
| US20050176780A1 (en) | 2005-08-11 |
| RU2004134563A (ru) | 2005-07-20 |
| DK1532111T3 (da) | 2007-10-22 |
| US7572817B2 (en) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102090780B1 (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| AU2006264051B2 (en) | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | |
| CA2144763A1 (en) | Fibrinogen receptor antagonists | |
| RU2365583C2 (ru) | 2,5-дизамещенные 3-меркаптопентановые кислоты и способ их получения | |
| ES2299026T3 (es) | Derivados de imidazol en calidad de inhibidores de tafia. | |
| CZ20013930A3 (cs) | Nové sloučeniny | |
| IL302837A (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| WO2003050088A1 (en) | Substituted heterocyclic carboxamides with antithrombotic activity | |
| JP2021102645A (ja) | メプリンアルファ及びベータの新規な阻害剤 | |
| KR20110025970A (ko) | 트롬빈 억제제로서 사용하기 위한 신규 복소환 카복스아미드 | |
| EP1259506A1 (en) | Pyrazinone thrombin inhibitors | |
| EP1899321B1 (en) | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | |
| HK1077296B (en) | 2,5-disubstituted 3-mercaptopentanoic acid | |
| EP1655296A1 (en) | Thrombin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20041213 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080604 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100628 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20101021 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20100628 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |